Credit Suisse’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Credit Suisse’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-20,292	Closed	-$107K	–	4602
2021 Q2	$107K	Buy	+20,292	New	+$97.6K	﹤0.01%	4361
2020 Q4	–	Sell	-14,867	Closed	-$49K	–	4480
2020 Q3	$49K	Buy	+14,867	New	+$54.6K	﹤0.01%	3958
2017 Q4	–	Sell	-11,473	Closed	-$96K	–	4251
2017 Q3	$96K	Buy	+11,473	New	+$121K	﹤0.01%	4101
2016 Q3	–	Sell	-16,335	Closed	-$111K	–	4301
2016 Q2	$111K	Buy	+16,335	New	+$137K	﹤0.01%	4039

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Credit Suisse's ZYNE Position: Q3 2021 in Review

Credit Suisse sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2021, closing a stake of 20,292 shares — an estimated $107K sold.

Credit Suisse first reported a position in ZYNE in Q2 2016 and held it in 4 quarters. The position peaked at $111K in Q2 2016. 58 funds tracked by Wall St. Rank hold ZYNE as of Q3 2021.

Credit Suisse reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2021 after selling out during the quarter.
Credit Suisse sold 20,292 Zynerba Pharmaceuticals, Inc shares in Q3 2021, an estimated $107K.
Credit Suisse first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2016 and held it in 4 quarters.
Credit Suisse's Zynerba Pharmaceuticals, Inc position peaked at $111K in Q2 2016.
58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2021.

Based on Credit Suisse's 13F filing for Q3 2021, filed 12 Nov 2021.